Cosmos Health Subsidiary Cana Laboratories Inaugurates New Capsule Production Line And Secures Additional Five-Year Contract With Provident Pharmaceuticals

Cosmos Health Inc

Cosmos Health Inc

COSM

0.00

Under the new five-year agreement, Cana will manufacture 385,000 units of CERTORUN® (sertraline hydrochloride) over the five-year period, at an annual production volume of 77,000 units. CERTORUN® is an antidepressant in the selective serotonin reuptake inhibitor (SSRI) class used to treat depression, anxiety, and related disorders. The product will be produced in two strengths — CERTORUN® Caps 50mg/cap (BTx30, blister 3x10) and CERTORUN® Caps 100mg/cap (BTx30, blister 3x10).

Production will take place on Cana's newly installed ACG capsule-filling line.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.